Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | HPGD | P15428 | 7/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.69 |
| ▸ | CA4 | P22748 | 1/20 | 0.69 |
| ▸ | CA6 | P23280 | 1/20 | 0.69 |
| ▸ | CA7 | P43166 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL28099781 | 0.89 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL28099779 | 0.89 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL28438472 | 0.89 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Phthalic Acid SCHEMBL120455 | 0.88 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Phthalic Acid SCHEMBL9417364 | 0.88 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Phthalic Acid SCHEMBL28858619 | 0.88 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL4194185 | 0.87 | ALDH1A1 (0.67) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Phthalic Acid SCHEMBL28184672 | 0.86 | ALDH1A1 (0.61) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| 2,3-Dihydroxybenzoic Acid SCHEMBL29001932 | 0.85 | SELL (0.52) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Mannitol SCHEMBL28437579 | 0.85 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4016264-A | Wart treatment with phosphonoacetic acid or derivatives thereof | THE UNIVERSITY OF UTAH (US) | 1977-04-05 | — | — | US | claimed |
| CN-115644177-B | Neutral peracetic acid disinfectant and preparation method thereof | 利康医药科技江苏有限公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-3652234-B1 | POLY(GLYCEROL SEBACATE)-INTERLEUKIN INHIBITOR COPOLYMERS AND METHODS OF MAKING | SECANT GROUP LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210024686-A1 | POLY(GLYCEROL SEBACATE)-INTERLEUKIN INHIBITOR COPOLYMERS AND METHODS OF MAKING AND USE | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2021-01-28 | — | — | US | disclosed |
| US-10822450-B2 | Poly(glycerol sebacate)-interleukin inhibitor copolymers and methods of making and use | THE SECANT GROUP LLC (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3652234-A1 | POLY(GLYCEROL SEBACATE)-INTERLEUKIN INHIBITOR COPOLYMERS AND METHODS OF MAKING AND USE | The Secant Group, LLC (US) | 2020-05-20 | — | — | EP | disclosed |
| CN-110612093-A | Topical formulations and methods | 麦欧赛普特股份有限公司 | 2019-12-24 | — | — | CN | disclosed |
| EP-2967045-B1 | PRESERVATIVE SYSTEM | MARY KAY INC (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-2019014349-A1 | POLY(GLYCEROL SEBACATE)-INTERLEUKIN INHIBITOR COPOLYMERS AND METHODS OF MAKING AND USE | THE SECANT GROUP, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20190016854-A1 | POLY(GLYCEROL SEBACATE)-INTERLEUKIN INHIBITOR COPOLYMERS AND METHODS OF MAKING AND USE | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2019-01-17 | — | — | US | disclosed |
| US-20140274974-A1 | PRESERVATIVE SYSTEM | MARY KAY INC. (US) | 2014-09-18 | — | — | US | disclosed |
| CN-101448482-B | Glyceryl and glycol acid compounds | MARY KAY INC | 2013-10-09 | — | — | CN | disclosed |
| CN-101448482-A | Glyceryl and glycol acid compounds | MARY KAY INC (US) | 2009-06-03 | — | — | CN | disclosed |
| WO-2003080062-A1 | COMPOSITION COMPRISING VITAMIN B9, VITAMIN B6, LIPOIC ACID AND PLANT EXTRACTS FOR TREATING CIRCULATORY DISORDERS | PERRELLA SEGRE SILVIA (IT) | 2003-10-02 | — | — | WO | disclosed |
| CN-1422147-A | Stable aqueous surfactant compositions | NOVEON IP HOLDINGS CORP (US) | 2003-06-04 | — | — | CN | disclosed |
| EP-0698393-B1 | 3-l-MENTHOXY-PROPANE-1, 2-DIOL AS SOLUBILIZING AGENT AND EXTERNAL PREPARATION CONTAINING THE SAME | HISAMITSU PHARMACEUTICAL CO (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-5725874-A | MENTHOXYPROPANEDIOL | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1998-03-10 | — | — | US | disclosed |
| US-5565207-A | CONTAINS A STEROID GLYCOSIDE AND/OR TRITERPENOID GLYCOSIDE, A SPHINGO GLYCOLIPID AND A STEROID HORMONE | POLA KASEI KOGYO KABUSHIKI KAISHA (JP) | 1996-10-15 | — | — | US | disclosed |
| EP-0698393-A1 | SOLUBILIZING AGENT AND EXTERNAL PREPARATION CONTAINING THE SAME | Hisamitsu Pharmaceutical Co., Inc. (JP) | 1996-02-28 | — | — | EP | disclosed |
| US-4886843-A | CALCIUM HYDROXIDE CEMENT CHARACTERISTICS AND LIGHT CURE CHARACTERISTICS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024686-A1 | POLY(GLYCEROL SEBACATE)-INTERLEUKIN INHIBITOR COPOLYMERS AND METHODS OF MAKING AND USE | IL2, IL17A, IL6 | ALDH1A1 861/4885HPGD 164/4885KDM4E 4127/4885 |
| US-20140274974-A1 | PRESERVATIVE SYSTEM | GSS, SPAST, MGLL | ALDH1A1 525/4885HPGD 482/4885KDM4E 4596/4885 |
| US-10822450-B2 | Poly(glycerol sebacate)-interleukin inhibitor copolymers and methods of making and use | PTGIS, GK, CHUK | ALDH1A1 2202/4885HPGD 63/4885KDM4E 3468/4885 |
| US-20190016854-A1 | POLY(GLYCEROL SEBACATE)-INTERLEUKIN INHIBITOR COPOLYMERS AND METHODS OF MAKING AND USE | IL2, IL17A, IL6 | ALDH1A1 861/4885HPGD 164/4885KDM4E 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.